Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
×
Share this article
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print

Diabetes Distilled: COVID-19 and diabetes: When two pandemics collide

In their commentary published on 31 March, authors from Sapienza University of Rome combine the earliest discussion of the increased risk of serious consequences of COVID-19 infection in people with diabetes in China with their own experience of studying the disease in Italy, to suggest possible mechanisms for the increased severity and to highlight potential treatment options that could target those specific mechanisms. They conclude that, although COVID-19 and diabetes are two pandemics with very different characteristics and healthcare burdens (acute versus chronic, communicable versus non-communicable), both have a serious impact on health and the interaction of the two may have not just short-term but also long-term consequences on people with diabetes.

Much of our initial understanding of the increased risk of serious COVID-19 infection in people with diabetes is based on data from the previous SARS, MERS and H1N1 influenza epidemics. Mortality rates as high as 16% have been reported from China in those with diabetes and COVID-19, compared to 1–2% in those without any co-morbidities (Guo et al, 2020).

Of concern is the fact that people with diabetes may initially have a milder presentation of COVID-19, with fewer classical symptoms of fever, chest tightness or dyspnoea. This is comparable to the lack of symptoms in the “silent myocardial infarction” sometimes seen in people with diabetes. In a commentary published on 31 March, Ernesto Maddaloni and Raffaella Buzzeti, from Sapienza University of Rome, suggest that this may cause a life-threatening delay in diagnosis and treatment, and they warn us not to underestimate the COVID-19 severity in people with diabetes who initially have mild symptoms.

There are far more questions than answers. The authors explore potential reasons for the increased severity. People with diabetes already have low-grade inflammation; might that facilitate a cytokine storm, which increases fatality? Could these changes, such as increased levels of interleukin-6, be specifically targeted with drug therapies used in autoimmune conditions, as is being trialled in some Italian hospitals to fight COVID-19?

The authors also share some of the unanswered questions from the original data coming out of China (Guo et al, 2020). Does COVID-19 have a different impact in those with type 1 compared with type 2 diabetes? Do the drugs we use to treat diabetes have differential effects on COVID-19 disease progression? Is the impact of ageing the same in those with diabetes as in the general population?

The commentary highlights that the relationship between COVID-19 and diabetes appears to be bidirectional, with COVID-19 infection worsening pre-existing diabetes or even predisposing to diabetes in people without the condition. What is not clear is whether this impact may continue over the longer term after the acute infection. Only monitoring of the long-term impact in those with diabetes who have had COVID-19 will answer this.
 
To access the publication, click here

Guo W, Li M, Dong Y et al (2020) Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev: e3319 [Epub ahead of print]

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.